Skip to main contentSkip to navigationSkip to search

About Curasight

Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology provides improved diagnosis and risk stratification in multiple cancer types, most notably for risk stratification in prostate cancer.

CSO and Co-Founder of Curasight Andreas Kjaer speaks at BioPharm America about Curasight developping novel, innovative radionuclide therapies for cancer.